Diabetes
Refine Search
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Pharmaceutical
French drug major Sanofi is to initially target newly-diagnosed patients with its recently-approved once-daily, long-acting basal insulin Toujeo (insulin glargine), but will not offer a discount against Lantus (insulin glargine), according to reports by Bloomberg. 14 April 2015
Pharmaceutical
An alarming rise in the cases of juvenile diabetes in India has got the government worried. Given the rising cases, especially with children under five and adolescents, free insulin is to be distributed by the Research Society for the Study of Diabetes in India to children below the age of 15 years across the country, reports The Pharma Letter’s India correspondent. 13 April 2015
Pharmaceutical
According to a preliminary review of data by US Food and Drug Administration reviewers, Anglo-Swedish pharma major AstraZeneca’s Onglyza (saxagliptin), a treatment for type 2 diabetes, may pose health risks. 11 April 2015
Pharmaceutical
Danish diabetes care giant Novo Nordisk today opened a new manufacturing facility in Russia for formulation and filling of modern insulin for the treatment of diabetes. 10 April 2015
Generics
The Russian General Prosecutor Office and the Federal Antimonopoly Service (FAS) have initiated a new wave of massive checks of national pharmacies and pharmaceutical producers, which are suspected of being responsible for a significant increase of prices for their products, reports The Pharma letter’s local correspondent. 9 April 2015
Pharmaceutical
The US Food and Drug Administration) has accepted for review Danish diabetes care giant Novo Nordisk’s Class II Resubmissions for its ultra long-acting insulins Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart), 8 April 2015
Biotechnology
Goldman Small Cap Research, a stock market research firm specializing on the small cap and microcap sectors, has issued a new article on PharmaCyte Biotech, a publicly-traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. 2 April 2015
Pharmaceutical
The Russian government plans to approve a new plan of import substitution in the national pharmaceutical industry shortly, according to Sergey Tsyb, Russia’s Deputy Minister of Industry and Trade, reports The Pharma Letter’s local correspondent. 1 April 2015
Pharmaceutical
Danish diabetes care giant Novo Nordisk plans to continue its expansion in the Russian pharmaceutical market during the next several years, despite the current unfavorable business environment in the country. 1 April 2015
Pharmaceutical
BioDelivery Sciences' shares were down up to 30% following the drugmaker’s announcement that its clonidine topical gel did not meet the primary endpoint of its Phase III trial. 31 March 2015
Pharmaceutical
The Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application of Zafatek (trelagliptin succinate), a drug for treating type 2 diabetes from Takeda Pharmaceutical. 30 March 2015
Pharmaceutical
Five new medicines have been recommended for approval at the March 2015 meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). 27 March 2015
Pharmaceutical
Danish diabetes care giant Novo Nordisk has decided to submit the pre-specified interim analysis of DEVOTE as part of a Class II Resubmission of the New Drug Applications of Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) to the US Food and Drug Administration. 27 March 2015
Pharmaceutical
Danish insulin giant Novo Nordisk has completed Phase IIIa trials comparing faster-acting insulin aspart with NovoRapid in type 1 and type 2 diabetes. 26 March 2015
Biotechnology
The US Food and Drug Administration today expanded the approved use for US biotech firm Regeneron’s Eylea (aflibercept) injection to treat diabetic retinopathy in patients with diabetic macular edema (DME). 25 March 2015
Pharmaceutical
The National Institute of Health and Care Excellence (NICE), the medicines cost watchdog for England and Wales, today announced several National Health Service funding decisions. 25 March 2015
Biotechnology
USA-based biotech start-up Semma Therapeutics, which is developing a cell therapy for type 1 diabetes, says it has closed a $44 million Series A consisting of equity financing and strategic funding. 25 March 2015
Pharmaceutical
Anglo-Swedish drug major AstraZeneca has entered into a five-year research collaboration with the Harvard Stem Cell institute to adapt a technique to create human beta cells from stem cells. 25 March 2015
Pharmaceutical
There was good news for Danish diabetes care giant Novo Nordisk yesterday, when, late in the day, the company announced that it had received European marketing authorization for Saxenda (liraglutide 3mg) for the treatment of obesity. 24 March 2015
Biotechnology
Privately-held US biotech firm Intarcia Therapeutics and Swiss firm Numab have announced a strategic collaboration focused on the development of once- or twice-yearly mono-specific and multi-specific antibodies addressing diabetes, obesity and autoimmune indications. 20 March 2015
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze